Patents
Literature
5 results about "Dysostosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A dysostosis is a disorder of the development of bone, in particular affecting ossification. Examples include craniofacial dysostosis, Klippel–Feil syndrome, and Rubinstein–Taybi syndrome. It is one of the two categories of constitutional disorders of bone (the other being osteochondrodysplasia).
Fgfr3 inhibitor compounds
This invention provides compounds of the following formula for treating systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:
Owner:ELI LILLY & CO
FGFR3 inhibitor compounds
The present invention relates to FGFR3 inhibitor compounds, and specifically provides compounds of the following formula: for use in the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), cartilage insufficiency, lethal insufficiency (e.g., Type I), severe cartilage insufficiency (SADDAN) accompanied by developmental retardation and rosmarthosis, muenke syndrome, or cancer.
Owner:ELI LILLY & CO
New FGFR3 inhibitor compound
PCT designated stageWO2026067385A1Organic active ingredientsGroup 5/15 element organic compoundsThanatophoric dysplasiaMuenke syndrome
The present invention relates to an FGFR3 selective inhibitor compound or a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer such as urothelial cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans, or Muenke syndrome.
Owner:SHANGHAI HUIKE BIOPHARMACEUTICAL CO LTD
FGFR3 inhibitor compounds
This invention relates to FGFR3 inhibitor compounds, and specifically, provides compounds of the following formula for the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:
Owner:ELI LILLY & CO
FGFR3 inhibitor compounds
This invention relates to FGFR3 inhibitor compounds, and specifically, provides compounds of the following formula for the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:
Owner:ELI LILLY & CO